drugset / Trial / NCT00673556

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

NCT00673556

Phase 3 Completed 195 enrolled Astellas Pharma Inc Biogen · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

To assess the efficacy and safety of Alefacept compared to placebo for the treatment of Chronic Plaque Psoriasis in patients for whom conventional therapies are ineffective and inappropriate

Timeline

Start
2003-10
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Alefacept Protein / enzyme biologic 15 mg Intramuscular

Indications